Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Acoramidis sequencing starts after ATTR-CM is confirmed, not before.
- Its role is disease modification within a longitudinal care plan, not rescue of fixed advanced myocardial damage.
- Persistence, stage, and supportive heart failure care shape how much benefit a stabilizer strategy can realistically deliver.
Sequencing Begins After the Diagnosis Is Secure
Treatment sequencing with acoramidis begins after the ATTR-CM diagnosis is secure, not before. Monoclonal-protein testing and an appropriate evaluation to exclude amyloid light chain (AL) amyloidosis still matter because sequencing decisions are only meaningful once the underlying amyloid type is clear.
Acoramidis Is Disease Modification, Not Rescue
Within confirmed ATTR-CM, acoramidis fits as a transthyretin stabilizer meant to slow disease progression, not to rescue fixed advanced myocardial damage. The relevant clinical question is not where acoramidis sits in a fixed treatment hierarchy, but whether the patient has sufficient physiological reserve, treatment continuity, and supportive heart failure care for a transthyretin stabilizer therapy to matter over time. Acoramidis should therefore be considered alongside tafamidis as an approved stabiliser within its labelled indication, rather than as a hierarchically ranked alternative.
Persistence and Stage Shape What Sequencing Can Deliver
Treatment persistence is an integral component of sequencing decisions. Recurrent decompensation, renal constraints, access barriers, or poor follow-up continuity can all limit what any disease-modifying agent delivers in routine care. Exploratory recurrent-event data may support the idea of longitudinal burden reduction, but they don’t replace the need for diagnostic confirmation, stage-aware expectations, or ongoing supportive management. The fuller evidence picture is covered in acoramidis evidence in ATTR-CM.
Clinical Decision Point
Acoramidis sequencing requires confirmation of diagnosis and assessment of clinical feasibility rather than adherence to a fixed-treatment hierarchy. It depends on whether ATTR-CM is securely diagnosed with AL excluded, whether enough reserve and modifiable disease remain for a stabilizer to matter, and whether continuity can be maintained. When those conditions hold, acoramidis is a reasonable label-bounded option; when functional reserve is limited or sustained treatment is unlikely to be achievable, the emphasis shifts toward supportive care and reassessment rather than escalation.
Frequently Asked Questions
What prerequisites must be met before acoramidis sequencing is considered?
The ATTR-CM diagnosis must be confirmed, with AL amyloidosis and mixed amyloid disease excluded, before acoramidis sequencing is considered. Monoclonal-protein testing and a coherent non-AL pathway come first.
Is acoramidis best thought of as a rescue therapy?
No. Acoramidis is a disease-modifying agent designed for long-term use within a longitudinal management plan. It slows progression rather than reversing fixed advanced myocardial damage.
Is acoramidis ranked above or below tafamidis?
No head-to-head trial establishes superiority between the two stabilizers, so sequencing is an individualized treatment decision based on phenotype, tolerability, access, and persistence rather than a fixed ranking.
What factors most commonly limit the effectiveness of sequencing in clinical practice?
Advanced stage, recurrent instability, limitations in treatment access, and inconsistent follow-up can all narrow what treatment continuity can achieve, regardless of which stabilizer is chosen.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- ATTRUBY (acoramidis) prescribing information. U.S. Food and Drug Administration
- Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. PubMed
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. PubMed
- Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.